Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 8Sarcoma 3Lymphoma, B-Cell 3Lymphoma 3Prostatic Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rhabdoid Tumor 1Recurrence 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Inhibition, Psychological 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Chordoma 1

Interventions

Cyclophosphamide 28fludarabine phosphate 22Peripheral Blood Stem Cell Transplantation 22Whole-Body Irradiation 18Etoposide 17Mycophenolic Acid 14Doxorubicin 13Tacrolimus 12Vincristine 11Prednisone 11Cyclosporine 11Methotrexate 10Busulfan 10Melphalan 9Bortezomib 9Rituximab 8Antilymphocyte Serum 8Filgrastim 7Carboplatin 7Radiotherapy 6Lenalidomide 6Everolimus 6romidepsin 5Vorinostat 5Therapeutics 5etoposide phosphate 4Sirolimus 4Panobinostat 4Immunohistochemistry 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immunoblastic Lymphadenopathy × tazemetostat × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡